161
Participants
Start Date
December 20, 2019
Primary Completion Date
January 30, 2026
Study Completion Date
January 30, 2026
M1774
M1774 will be administered orally throughout the study.
Niraparib
Niraparib will be administered orally throughout the study.
Mary Crowley Cancer Research Centers, Dallas
The Methodist Hospital Research Institute, Houston
University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics, Houston
NEXT Oncology, Austin
Massachusetts General Hospital, Boston
Beijing Cancer Hospital, Beijing
National Cancer Center Hospital - Dept of Experimental Therapeutics, Chūōku
National Cancer Center Hospital East - Dept of Experimental Therapeutics, Kashiwa-shi
Hospital Clinic de Barcelona - Servicio de Oncologia, Barcelona
Hospital Universitari Vall d'Hebron - Oncology Dept., Barcelona
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica, Madrid
Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica, Valencia
Addenbrooke's Hospital - Dept of Oncology, Cambridge
The Christie Hospital - Dept of Oncology, Manchester
Northern Centre for Cancer Care - Sir Bobby Robson Cancer Trials Research Centre, Newcastle upon Tyne
Royal Marsden Hospital - Dept of Oncology, Sutton
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY